280 related articles for article (PubMed ID: 26308597)
1. Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.
Bozeman EN; He S; Shafizadeh Y; Selvaraj P
Hum Vaccin Immunother; 2016; 12(2):421-30. PubMed ID: 26308597
[TBL] [Abstract][Full Text] [Related]
2. Induction of T-cell apoptosis in rats by genetically engineered glioma cells expressing granulocyte-macrophage colony-stimulating factor and B7.1.
Tseng SH; Chen Y; Chang CJ; Tai KF; Lin SM; Hwang LH
Clin Cancer Res; 2005 Feb; 11(4):1639-49. PubMed ID: 15746069
[TBL] [Abstract][Full Text] [Related]
3. Immune responsiveness to a murine mammary carcinoma modified to express B7-1, interleukin-12, or GM-CSF.
Aruga E; Aruga A; Arca MJ; Lee WM; Yang NS; Smith JW; Chang AE
Cancer Gene Ther; 1997; 4(3):157-66. PubMed ID: 9171934
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib combined with HER-2 targeted vaccination can promote effective T cell immunity in vivo.
Sunay MM; Foote JB; Leatherman JM; Edwards JP; Armstrong TD; Nirschl CJ; Hicks J; Emens LA
Int Immunopharmacol; 2017 May; 46():112-123. PubMed ID: 28282575
[TBL] [Abstract][Full Text] [Related]
5. Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model.
Bozeman EN; Cimino-Mathews A; Machiah DK; Patel JM; Krishnamoorthy A; Tien L; Shashidharamurthy R; Selvaraj P
Vaccine; 2013 May; 31(20):2449-56. PubMed ID: 23541884
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody.
Pilon SA; Piechocki MP; Wei WZ
J Immunol; 2001 Sep; 167(6):3201-6. PubMed ID: 11544306
[TBL] [Abstract][Full Text] [Related]
7. PD-1/PD-L1 blockade enhances the efficacy of SA-GM-CSF surface-modified tumor vaccine in prostate cancer.
Shi X; Zhang X; Li J; Zhao H; Mo L; Shi X; Hu Z; Gao J; Tan W
Cancer Lett; 2017 Oct; 406():27-35. PubMed ID: 28797844
[TBL] [Abstract][Full Text] [Related]
8. Sequential Anti-PD1 Therapy Following Dendritic Cell Vaccination Improves Survival in a HER2 Mammary Carcinoma Model and Identifies a Critical Role for CD4 T Cells in Mediating the Response.
Kodumudi KN; Ramamoorthi G; Snyder C; Basu A; Jia Y; Awshah S; Beyer AP; Wiener D; Lam L; Zhang H; Greene MI; Costa RLB; Czerniecki BJ
Front Immunol; 2019; 10():1939. PubMed ID: 31475002
[TBL] [Abstract][Full Text] [Related]
9. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
[TBL] [Abstract][Full Text] [Related]
10. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
[TBL] [Abstract][Full Text] [Related]
11. PD-1 blockade enhances the antitumor efficacy of GM-CSF surface-modified bladder cancer stem cells vaccine.
Shi X; Zhang X; Li J; Mo L; Zhao H; Zhu Y; Hu Z; Gao J; Tan W
Int J Cancer; 2018 May; 142(10):2106-2117. PubMed ID: 29243219
[TBL] [Abstract][Full Text] [Related]
12. CD27 Agonism Plus PD-1 Blockade Recapitulates CD4+ T-cell Help in Therapeutic Anticancer Vaccination.
Ahrends T; Bąbała N; Xiao Y; Yagita H; van Eenennaam H; Borst J
Cancer Res; 2016 May; 76(10):2921-31. PubMed ID: 27020860
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
McArthur HL; Page DB
Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
[TBL] [Abstract][Full Text] [Related]
14. GM-CSF and B7-1 (CD80) co-stimulatory signals co-operate in the induction of effective anti-tumor immunity in syngeneic mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Hamada H; Azuma M; Asano S
Int J Cancer; 1997 Nov; 73(4):556-61. PubMed ID: 9389572
[TBL] [Abstract][Full Text] [Related]
15. B7-1 (CD80)-gene transfer combined with interleukin-12 administration elicits protective and therapeutic immunity against mouse hepatocellular carcinoma.
Tatsumi T; Takehara T; Kanto T; Kuzushita N; Ito A; Kasahara A; Sasaki Y; Hori M; Hayashi N
Hepatology; 1999 Aug; 30(2):422-9. PubMed ID: 10421650
[TBL] [Abstract][Full Text] [Related]
16. An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.
Rice AE; Latchman YE; Balint JP; Lee JH; Gabitzsch ES; Jones FR
Cancer Gene Ther; 2015 Sep; 22(9):454-62. PubMed ID: 26337747
[TBL] [Abstract][Full Text] [Related]
17. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
[TBL] [Abstract][Full Text] [Related]
18. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
[TBL] [Abstract][Full Text] [Related]
19. HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.
Wolpoe ME; Lutz ER; Ercolini AM; Murata S; Ivie SE; Garrett ES; Emens LA; Jaffee EM; Reilly RT
J Immunol; 2003 Aug; 171(4):2161-9. PubMed ID: 12902523
[TBL] [Abstract][Full Text] [Related]
20. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.
Hurwitz AA; Yu TF; Leach DR; Allison JP
Proc Natl Acad Sci U S A; 1998 Aug; 95(17):10067-71. PubMed ID: 9707601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]